大分割立体定向放疗治疗复发恶性胶质瘤的系统综述与荟萃分析
该系统综述与荟萃分析纳入26项研究共861例复发恶性胶质瘤患者,评估大分割立体定向放疗(HFSRT)的疗效与安全性。中位总生存期为8.6至18个月,放射性坏死 pooled 率为5%(3%-7%),其他主要神经并发症 pooled 率为2%(1%-4%)。结论认为HFSRT有效且安全,但纳入研究的回顾性观察性质限制了更确凿结论的形成。
要点
- HFSRT治疗复发恶性胶质瘤的中位总生存期为8.6至18个月。
- 放射性坏死 pooled 率为5%(3%-7%),其他主要神经并发症为2%(1%-4%)。
- 证据受回顾性研究限制,需前瞻性对照试验进一步明确治疗地位。
核心结论
- 现有证据提示HFSRT是治疗复发恶性胶质瘤有效且安全的方法。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase和Cochrane Library,纳入26项研究共861例患者。
主要发现
- 中位总生存期范围为8.6至18个月。
- 19项研究汇总的放射性坏死率为5%(3%-7%)。
- 20项研究汇总的其他主要神经并发症率为2%(1%-4%)。
临床怎么用
- HFSRT可作为复发恶性胶质瘤的治疗选择,需关注放射性坏死等并发症。
局限性
- 纳入研究为回顾性和观察性,限制了更确凿结论的形成。
- 需要精心设计的前瞻性对照试验进一步明确HFSRT的治疗作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current treatment for patients with relapsed malignant glioma (MG) remains unsatisfactory. Use of hypofractionated stereotactic radiotherapy (HFSRT) for recurrent MG has shown some encouraging results and may be a viable option. METHODS: We performed a systematic review and meta-analysis of articles that investigated the use of HFSRT for recurrent MG. Relevant studies were obtained through searching PubMed, Embase, and the Cochrane Library. Data about treatment regimens, median overall survival, and radiation necrosis (RN), as well as other major neurologic complications were extracted. We performed a descriptive analysis of the median overall survival and meta-analysis of the reported rates of RN and other major neurologic complications (MNCs). RESULTS: A total of 26 studies were included in our study, comprising 861 patients. Median overall survival ranged from 8.6 to 18 months. A total of 19 studies were included to perform a meta-analysis of the RN rate and the pooled RN rate was 5% (3%-7%). The pooled rate of other MNCs was 2% (1%-4%), calculated from 20 studies. CONCLUSIONS: The present evidence suggests that HFSRT is an efficacious and safe treatment approach to treat patients with recurrent MG. However, the retrospective and observational nature of the studies included in our systematic review and meta-analysis restricted formation of more solid conclusions. Thus, well-designed prospective controlled trials are warranted to further define the therapeutic role of HFSRT for recurrent MG.
引用
- Hu YJ, Chen D, Zhang LF, et al. Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy for Recurrent Malignant Gliomas: A Systematic Review and Meta-analysis. World Neurosurg. 2019. PMID: 30959254. doi:10.1016/j.wneu.2019.03.297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。